Efficacy News and Research

RSS
Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Amarin reports $31.4 million cash balance for third quarter 2010

Amarin reports $31.4 million cash balance for third quarter 2010

Receptive music therapy associated with reduced depressive symptoms

Receptive music therapy associated with reduced depressive symptoms

Hospitals need to work more to prevent heart attack deaths: Study

Hospitals need to work more to prevent heart attack deaths: Study

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Nuffield Health Leeds Hospital offers incisionless TOGA Procedure for treatment of obesity

Nuffield Health Leeds Hospital offers incisionless TOGA Procedure for treatment of obesity

Repros third quarter net loss decreases to $1.2 million

Repros third quarter net loss decreases to $1.2 million

Jefferson awarded $2.6M grant for study on cognitive decline in older African Americans with MCI

Jefferson awarded $2.6M grant for study on cognitive decline in older African Americans with MCI

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Regional workshop to discuss diarrheal disease solutions for Asia

Regional workshop to discuss diarrheal disease solutions for Asia

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix partners with Genscript to develop human antibody therapeutics

FlexStent Femoropopliteal SE Stent System FIM study results presented at VIVA conference

FlexStent Femoropopliteal SE Stent System FIM study results presented at VIVA conference

MicroAire and Arthrex enter agreement to settle ECTR patent infringement suit

MicroAire and Arthrex enter agreement to settle ECTR patent infringement suit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.